Clinical study of 0.15 ％ brimonidine tartrate eye drops for the treatment of primary open angle glaucoma and ocular hypertension

Abstract

Objective To investigate the efficacy and safety of 0.15％ brimonidine tartrate (Alphagan P)eye drops.Methods 86 eyes of 46 cases with primary open angle glaucoma (POAG) or ocular hypertension were dosed with Alphagan P eye drops alone or as an adjunctive therapy as one drop a time,thrice daily.The intraocular pressure (IOP) at 2,4,8 and 12 weeks after sustained instilling were compared with the baseline.On the other hand,systematic and local adverse effects were also observed.Results Alphagan P eye drops reduced IOP significantly.The mean IOP decreased from the baseline (22.89 ±3.91)mmHg(1 mmHg =0.133 kPa) to(19.43 ±2.84),(19.43 ±3.44),(18.98 ±3.17)and (18.87 ± 2.83)mmHg at 2,4,8 and 12 weeks after sustained instilling respectively.There were statistical differences between baseline and the IOP at four time points (P ＜ 0.01).No matter dropped Alphagan P alone or taken it as an adjunctive therapy or switched to Alphagan P during trentment,there were statistical differences between baseline and the IOP at four time points after sustained instilling (P ＜ 0.01).The major adverse effects didn' t affect continuous medication.Conclusion Alphagan P eye drops can reduce IOP significantly in the patients with POAG or ocular hypertension.It is safe and effective. Key words: Eye drops, brimonidine tartrate, 0.15％ ; Eye drops, Alphagan P; Glaucoma